Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684799 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
A Phase 1 study, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02684799 is a Phase 1 study that has completed, run by Tobira Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT02684799, a Phase 1 study, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Interventions
- DRUG Omeprazole
- DRUG Famotidine
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-01-31 |
| Est. Completion | 2016-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684799
The ClinicalTrials.gov registry entry for NCT02684799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Omeprazole is the first listed.
NCT02684799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684799 about?
NCT02684799 is a clinical study titled "Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination". This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
What is the current status of trial NCT02684799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-01-31. Estimated completion is 2016-04-11.
What interventions are being tested in trial NCT02684799?
The interventions under investigation include: Omeprazole (DRUG), Famotidine (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT02684799?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.